According to the WHO’s Chief Scientist, India’s Phase-3 Trial Data Of India Made Covaxin looks promising

who-chief-scientist-says-phase-3-trial-data-of-india-made-covaxin-looks-good

According to WHO Chief Scientist Soumya Swaminathan, Covaxin’s Phase-3 trial data looks promising, and the vaccine should be approved by the WHO by mid to August. Her statement comes as Bharat Biotech awaits WHO approval for Covaxin’s emergency use listing.

While Hyderabad-based pharma firm Bharat Biotech awaits World Health Organization approval for Covaxin’s emergency use listing, WHO Chief Scientist Soumya Swaminathan has stated that Covaxin’s Phase-3 data looks promising and that the vaccine could be approved by the WHO by mid to late August.

Swaminathan stated in a interview that the Phase-3 trial data for Covaxin looks promising, and that all indications are that the efficacy and safety profile meet the WHO benchmarks.

“I believe the Phase-3 trial data (for Covaxin) are positive and encouraging. The good news is that they have looked at the variants and have sequenced approximately 60% of the breakthrough variants found in the trial. Overall efficacy is high, while efficacy against the Delta variant is lower, but still very good,” she explained.

Also Read  The Finance Minister will issue a White Paper.

“All indications are that the efficacy and safety profile meet WHO standards. However, the details will be reviewed by the pre-qualification and regulatory teams,” she added.

Swaminathan explained the current of Covaxin approval at the WHO, saying, “Currently, the pre-submission meeting held on June 23, and the data package is currently being submitted and assembled.” Then it will be reviewed by a group that will look at safety, quality, good manufacturing practices, and a number of parameters that Bharat Biotech is well-versed in. “We hope to have a decision on whether or not Covaxin will be approved for emergency use by mid to late August,” she said.

On Saturday of last , Bharat Biotech announced the Phase-3 clinical trial data for Covaxin. According to the trial report, Covaxin is 77.8 percent effective against symptomatic Covid-19.

The indigenously developed vaccine was 93.4 percent effective against severe symptomatic Covid-19 and 63.6 percent effective against asymptomatic Covid-19.

Also Read  NTA Releases Notice Regarding IMEI Registration Portal Not Working

Covaxin was found to be 63.6 percent effective against the Delta variant of Covid-19, which was responsible for India’s severe second coronavirus wave in April-May of this year.

Covaxin has already been approved for emergency use in 16 countries around the world, including Brazil, India, the Philippines, Iran, and Mexico.

You may also like:


Read full story at Nepal123.com

Nepal123.comhttps://nep123.com
Online since 2001, Nepal123.com is one of the oldest infotainment portals in Nepal.

More from author

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related posts

Latest posts

Sinti waterfall lures more domestic tourists

NARAYANGADH: Sinti waterfall located at Kalika Municipality-9 Chitwan district has received more domestic tourists in the recent days. Chairman of ward no. 9 of...

UML row: UML leaders Nepal and Poudel to hold talks today

KATHMANDU: CPN-UML leaders Madhav Kumar Nepal and Bishnu Poudel are scheduled to hold talks in a bid to thrash out intraparty disputes of the...

KSI: Starting small, growing big

KATHMANDU: British YouTuber KSI is a blend of personality, talent, and entertainment having more than 21 million subscribers. Although his real name is Olajide...

Want to stay up to date with the latest news?

We would love to hear from you! Please fill in your details and we will stay in touch. It's that simple!

According to the WHO’s Chief Scientist, India’s Phase-3 Trial Data Of India Made Covaxin looks promising

who-chief-scientist-says-phase-3-trial-data-of-india-made-covaxin-looks-good

According to WHO Chief Scientist Soumya Swaminathan, Covaxin’s Phase-3 trial data looks promising, and the vaccine should be approved by the WHO by mid to late August. Her statement comes as Bharat Biotech awaits WHO approval for Covaxin’s emergency use listing.

While Hyderabad-based pharma firm Bharat Biotech awaits World Health Organization approval for Covaxin’s emergency use listing, WHO Chief Scientist Soumya Swaminathan has stated that Covaxin’s Phase-3 data looks promising and that the vaccine could be approved by the WHO by mid to late August.

Swaminathan stated in a recent interview that the Phase-3 trial data for Covaxin looks promising, and that all indications are that the efficacy and profile meet the WHO benchmarks.

“I believe the Phase-3 trial data (for Covaxin) are positive and encouraging. The good news is that they have looked at the variants and have sequenced approximately 60% of the breakthrough variants found in the trial. Overall efficacy is high, while efficacy against the variant is lower, but still very good,” she explained.

Also Read  Bodies of 24 Nepali migrant workers brought to Nepal from Malaysia

“All indications are that the efficacy and safety profile meet WHO . However, the details will be reviewed by the pre-qualification and regulatory teams,” she added.

Swaminathan explained the current status of Covaxin approval at the WHO, saying, “Currently, the pre-submission was held on June 23, and the data package is currently being submitted and assembled.” Then it will be reviewed by a that will look at safety, quality, good manufacturing practices, and a number of parameters that Bharat Biotech is well-versed in. “We hope to have a decision on whether or not Covaxin will be approved for emergency use by mid to late August,” she said.

On Saturday of last week, Bharat Biotech announced the Phase-3 clinical trial data for Covaxin. According to the trial report, Covaxin is 77.8 percent effective against symptomatic Covid-19.

The indigenously developed vaccine was 93.4 percent effective against severe symptomatic Covid-19 and 63.6 percent effective against asymptomatic Covid-19.

Also Read  The Finance Minister will issue a White Paper.
Also Read  Another milestone for Worldlink: 500,000 households served

Covaxin was found to be 63.6 percent effective against the Delta variant of Covid-19, which was responsible for ’s severe second coronavirus wave in April-May of this year.

Covaxin has already been approved for emergency use in 16 countries around the world, including Brazil, India, the Philippines, Iran, and Mexico.

may also like:


Read full story at Nepal123.com

Nepal123.comhttps://nep123.com
Online since 2001, Nepal123.com is one of the oldest infotainment portals in Nepal.

More from author

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related posts

Latest posts

Sinti waterfall lures more domestic tourists

NARAYANGADH: Sinti waterfall located at Kalika Municipality-9 Chitwan district has received more domestic tourists in the recent days. Chairman of ward no. 9 of...

UML row: UML leaders Nepal and Poudel to hold talks today

KATHMANDU: CPN-UML leaders Madhav Kumar Nepal and Bishnu Poudel are scheduled to hold talks in a bid to thrash out intraparty disputes of the...

KSI: Starting small, growing big

KATHMANDU: British YouTuber KSI is a blend of personality, talent, and entertainment having more than 21 million subscribers. Although his real name is Olajide...

Want to stay up to date with the latest news?

We would love to hear from you! Please fill in your details and we will stay in touch. It's that simple!

According to the WHO’s Chief Scientist, India’s Phase-3 Trial Data Of India Made Covaxin looks promising

who-chief-scientist-says-phase-3-trial-data-of-india-made-covaxin-looks-good

According to WHO Chief Scientist Soumya Swaminathan, Covaxin’s Phase-3 trial data looks promising, and vaccine should be approved by the WHO by mid to late August. Her statement comes as Bharat Biotech awaits WHO approval for Covaxin’s emergency use listing.

While Hyderabad-based pharma firm Bharat Biotech awaits World Organization approval for Covaxin’s emergency use listing, WHO Chief Scientist Soumya Swaminathan has stated Covaxin’s Phase-3 data looks promising and that the vaccine could be approved by the WHO by mid to late August.

Swaminathan stated in a recent interview that the Phase-3 trial data for Covaxin looks promising, and that all indications are that the efficacy and safety profile meet the WHO benchmarks.

“I believe the Phase-3 trial data (for Covaxin) are and encouraging. The good news is that they have looked at the variants and have sequenced approximately 60% of the breakthrough variants found in the trial. Overall efficacy is high, while efficacy against the Delta variant is lower, but still very good,” she explained.

Also Read  NTA Releases Notice Regarding IMEI Registration Portal Not Working

“All indications are that the efficacy and safety profile meet WHO standards. However, the details will be reviewed by the pre-qualification and regulatory teams,” she added.

Swaminathan explained the current status of Covaxin approval at the WHO, saying, “Currently, the pre-submission was held on June 23, and the data package is currently being submitted and assembled.” Then it will be reviewed by a group that will look at safety, quality, good manufacturing practices, and a number of parameters that Bharat Biotech is well-versed in. “We hope to have a decision on whether or not Covaxin will be approved for emergency use by mid to late August,” she said.

On Saturday of last week, Bharat Biotech announced the Phase-3 clinical trial data for Covaxin. According to the trial report, Covaxin is 77.8 percent effective against symptomatic Covid-19.

The indigenously developed vaccine was 93.4 percent effective against severe symptomatic Covid-19 and 63.6 percent effective against asymptomatic Covid-19.

Also Read  Couple killed in Damak road accident

Covaxin was found to be 63.6 percent effective against the Delta variant of Covid-19, which was responsible for India’s severe second coronavirus wave in April-May of this year.

Covaxin has already been approved for emergency use in 16 countries around the world, including Brazil, India, the Philippines, Iran, and Mexico.

You may also like:


Read full story at Nepal123.com

Nepal123.comhttps://nep123.com
Online since 2001, Nepal123.com is one of the oldest infotainment portals in Nepal.

More from author

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related posts

Latest posts

Sinti waterfall lures more domestic tourists

NARAYANGADH: Sinti waterfall located at Kalika Municipality-9 Chitwan district has received more domestic tourists in the recent days. Chairman of ward no. 9 of...

UML row: UML leaders Nepal and Poudel to hold talks today

KATHMANDU: CPN-UML leaders Madhav Kumar Nepal and Bishnu Poudel are scheduled to hold talks in a bid to thrash out intraparty disputes of the...

KSI: Starting small, growing big

KATHMANDU: British YouTuber KSI is a blend of personality, talent, and entertainment having more than 21 million subscribers. Although his real name is Olajide...

Want to stay up to date with the latest news?

We would love to hear from you! Please fill in your details and we will stay in touch. It's that simple!

According to the WHO’s Chief Scientist, India’s Phase-3 Trial Data Of India Made Covaxin looks promising

who-chief-scientist-says-phase-3-trial-data-of-india-made-covaxin-looks-good

According to WHO Chief Scientist Soumya Swaminathan, Covaxin’s Phase-3 trial data looks promising, and the vaccine should be approved by the WHO by mid to late August. Her statement comes as Bharat Biotech awaits WHO approval for Covaxin’s emergency use listing.

While Hyderabad-based pharma firm Bharat Biotech awaits World Organization approval for Covaxin’s emergency use listing, WHO Chief Scientist Soumya Swaminathan has stated that Covaxin’s Phase-3 data looks promising and that the vaccine could be approved by the WHO by mid to late August.

Swaminathan stated in a recent interview that the Phase-3 trial data for Covaxin looks promising, and that all indications are that the efficacy and safety meet the WHO benchmarks.

“I believe the Phase-3 trial data (for Covaxin) are positive and encouraging. The good news is that they have looked at the variants and have sequenced approximately 60% of the breakthrough variants found in the trial. Overall efficacy is high, while efficacy against the Delta variant is lower, but still very good,” she explained.

Also Read  Samsung Galaxy M21 2021 Edition Announced with FHD+ sAMOLED, And Exynos 9611

“All indications are that the efficacy and safety profile meet WHO standards. However, the details will be reviewed by the pre-qualification and regulatory teams,” she .

Swaminathan explained the current status of Covaxin approval at the WHO, saying, “Currently, the pre-submission meeting was held on June 23, and the data package is currently being submitted and assembled.” Then it will be reviewed by a group that will look at safety, quality, good manufacturing practices, and a number of parameters that Bharat Biotech is well-versed in. “We hope to have a decision on whether or Covaxin will be approved for emergency use by mid to late August,” she said.

On Saturday of last week, Bharat Biotech announced the Phase-3 clinical trial data for Covaxin. According to the trial report, Covaxin is 77.8 percent effective against symptomatic Covid-19.

The indigenously developed vaccine was 93.4 percent effective against severe symptomatic Covid-19 and 63.6 percent effective against asymptomatic Covid-19.

Also Read  Today’s gold price increased by Rs 100 per tola

Covaxin was found to be 63.6 percent effective against the Delta variant of Covid-19, which was responsible for India’s severe second coronavirus wave in -May of this year.

Covaxin has already been approved for emergency use in 16 countries around the world, including Brazil, India, the Philippines, Iran, and Mexico.

You may also like:


Read full story at Nepal123.com

Nepal123.comhttps://nep123.com
Online since 2001, Nepal123.com is one of the oldest infotainment portals in Nepal.

More from author

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related posts

Latest posts

Sinti waterfall lures more domestic tourists

NARAYANGADH: Sinti waterfall located at Kalika Municipality-9 Chitwan district has received more domestic tourists in the recent days. Chairman of ward no. 9 of...

UML row: UML leaders Nepal and Poudel to hold talks today

KATHMANDU: CPN-UML leaders Madhav Kumar Nepal and Bishnu Poudel are scheduled to hold talks in a bid to thrash out intraparty disputes of the...

KSI: Starting small, growing big

KATHMANDU: British YouTuber KSI is a blend of personality, talent, and entertainment having more than 21 million subscribers. Although his real name is Olajide...

Want to stay up to date with the latest news?

We would love to hear from you! Please fill in your details and we will stay in touch. It's that simple!